SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

IM-1340

IMNM·Immunome Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
IND cleared / Phase 1 ready
Time to market
IM-1340 has just received IND clearance and has not yet begun patient dosing. If Phase 1 proceeds successfully, a registrational path would likely require several more years of clinical development.
Why 2/10
No hard dated catalyst is scheduled for IM-1340 in the next ~12 months; the IND was cleared in October 2026 enabling a Phase 1 start, but no Phase 1 data readout or regulatory decision date has been announced. The drug is a minor early-stage asset at a company whose valuation is dominated by varegacestat (PDUFA April 28, 2027).
Actionable Insight NEUTRAL

IM-1340 has no near-term binary catalyst; the stock is driven by varegacestat's PDUFA on April 28, 2027. Watch for Phase 1 trial initiation and any early data disclosures, but these are unlikely to move the stock significantly given the early stage. The next company-wide event is Q3 2026 earnings on November 16, 2026.

Price Chart

Loading chart...

Executive Summary

IM-1340 is an early-stage, potential first-in-class antibody-drug conjugate (ADC) for advanced solid tumors developed by Immunome Inc. (Nasdaq: IMNM). The FDA cleared its Investigational New Drug (IND) application in late September/early October 2026, enabling the company to begin a Phase 1 clinical trial focused on safety. The specific target antigen has not been publicly disclosed. IM-1340 is a minor pipeline asset at Immunome, which is primarily valued for its lead drug varegacestat (PDUFA April 28, 2027 for desmoid tumors). The stock trades at $19.07 with a strong analyst consensus (mean price target $35.20, 84.6% implied upside), but the company is pre-revenue and burning cash. IM-1340 has no near-term binary catalyst and is unlikely to be a meaningful stock-price driver in the next 12 months.

How It Works

IM-1340 is an antibody-drug conjugate (ADC), a type of cancer therapy that works like a guided missile. It combines an antibody (which seeks out and binds to a specific protein on cancer cells) with a potent chemotherapy drug. The antibody delivers the drug directly to tumor cells, aiming to kill them while sparing healthy tissue. The specific target protein has not been publicly disclosed.

Trial Status

The FDA cleared Immunome's Investigational New Drug (IND) application for IM-1340 in late September/early October 2026, allowing the company to initiate a Phase 1 first-in-human trial focused on safety and tolerability in advanced solid tumors. Patient enrollment has not yet been publicly announced as of mid-November 2026.

The Two-Sided Case

▲ Bull Case3
IM-1340 is described as a 'potential first-in-class' ADC, which could target a novel antigen and address an unmet need in advanced solid tumors if clinical data prove favorable.
Immunome has a strong ADC platform with proprietary topoisomerase I inhibitor payload (HC74), also used in IM-1021 and IM-1617, creating potential pipeline synergy.
Analyst consensus on Immunome is overwhelmingly bullish (21 of 23 analysts at Buy/Strong Buy) with a mean price target of $35.20, implying 84.6% upside from the current $19.07.
▼ Bear Case4
IM-1340 is a preclinical-to-Phase 1 asset with no disclosed target antigen, making it impossible to assess differentiation vs. the crowded ADC landscape.
The stock fell 6.5% on the IND clearance news, suggesting the market viewed the event as a non-catalyst or even a distraction from the lead varegacestat program.
Immunome is pre-revenue and burning cash ($85.8M net loss in Q3 2026 per the Q3 report), and early-stage pipeline additions add to R&D spend without near-term revenue prospects.
Insider selling has been notable, with executives selling over $2.9M in shares since August 2026, per SEC Form 4 filings.

Upcoming Catalysts

  • Phase 1 trial initiation announcement (no specific date announced)
  • Any early safety/tolerability data disclosures (timing uncertain, likely 2027+)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Immunome Inc. 8-K IMNM ·Originating report

Sources · 5

Hover a chip for the title
1 aol.com2 businesswire.com3 aol.com4 msn.com5 theglobeandmail.com